Cited by 244Epilepsy research and treatmentPharmacological Effects and Toxicity StudiesNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 96 of the 98 references it cites were found in a registry or an index.

Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)

Open access

Bialer, Meir, Johannessen, Svein I., Levy, René H., Perucca, Emilio, Tomson, Torbjörn, White, H. Steve·2013·Epilepsy Research

DOI 10.1016/j.eplepsyres.2012.10.001

Open this paper in CoChat — free account Open PDF

Abstract

The Eleventh Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT XI, took place in Eilat, Israel from the 6th to 10th of May 2012. About 100 basic scientists, clinical pharmacologists and neurologists from 20 countries attended the conference, whose main themes included "Indications overlapping with epilepsy" and "Securing the successful development of an investigational antiepileptic drug in the current environment". Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 1994. Like the EILAT X report, the current manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development. These include brivaracetam, 2-deoxy-glucose, ganaxolone, ICA-105665, imepitoin, NAX 801-2, perampanel and other AMPA receptor antagonists, tonabersat, valnoctamide and its homologue sec-propylbutylacetamide (SPD), VX-765 and YK3089. Since the previous Eilat conference, retigabine (ezogabine) has been marketed and four newer AEDs in development (NAX 810-2, SPD, tonabersat and VX-765) are included in this manuscript.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.eplepsyres.2012.10.001

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
The neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1430 · Cited by 1,243
Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites
Hosie, A. M., Wilkins, M. E., da Silva, H. M. A., & Smart, T. G. (2006) · Nature · doi:10.1038/nature05324 · Cited by 752
Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy
Barton, M. E., Klein, B. D., Wolf, H. H., & White, H. S. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00302-3 · Cited by 614
Self-citation
An update on GABAA receptors
Mehta, A. K., & Ticku, M. K. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00052-6 · Cited by 613
The role of cytokines in the pathophysiology of epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2008.03.009 · Cited by 564
Key factors in the discovery and development of new antiepileptic drugs
Bialer, M., & White, H. S. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2997 · Cited by 544
Self-citation
The Treatment of Epilepsy
(2004) · Wiley eBooks · doi:10.1002/9780470752463 · Cited by 509
Adjunctive perampanel for refractory partial-onset seizures
French, J. A., Krauss, G. L., Biton, V., Squillacote, D., Yang, H., Laurenza, A., Kumar, D., Rogawski, M. A., Campanille, V., Floridia, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635735 · Cited by 478
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Self-citation
2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP–dependent metabolic regulation of chromatin structure
Garriga-Canut, M., Schoenike, B. A., Qazi, R., Bergendahl, K., Daley, T. J., Pfender, R. M., Morrison, J. F., Ockuly, J. C., Stafstrom, C. E., Sutula, T. P., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1791 · Cited by 446
Randomized phase III study 306
Krauss, G. L., Serratosa, J. M., Villanueva, V., Endzinienė, M., Hong, Z., French, J. A., Yang, H., Squillacote, D., Edwards, H. B., Zhu, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318254473a · Cited by 430
Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305
French, J. A., Krauss, G. L., Steinhoff, B. J., Squillacote, D., Yang, H., Kumar, D., & Laurenza, A. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03638.x · Cited by 423
Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy
Hanada, T., Hashizume, Y., Tokuhara, N., Takenaka, O., Kohmura, N., Ogasawara, A., Hatakeyama, S., Ohgoh, M., Ueno, M., & Nishizawa, Y. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03109.x · Cited by 411
Development of new antiepileptic drugs: challenges, incentives, and recent advances
Perucca, E., French, J. A., & Bialer, M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70215-6 · Cited by 338
Self-citation
(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2 R,3 S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1β and IL-18
Wannamaker, W., Davies, R., Namchuk, M., Pollard, J., Ford, P., Ku, G., Decker, C., Charifson, P., Weber, P., Germann, U. A., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111344 · Cited by 315
Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies
Stein, M., Lin, H., Jeyamohan, C., Dvorzhinski, D., Gounder, M., Bray, K., Eddy, S., Goodin, S., White, E., & DiPaola, R. S. (2010) · The Prostate · doi:10.1002/pros.21172 · Cited by 291
Electrical Stimulation of the Anterior Nucleus of the Thalamus for Intractable Epilepsy: A Long‐term Follow‐up Study
Lim, S., Lee, S., Tsai, Y., Chen, I.-A., Tu, P., Chen, J., Chang, H., Su, Y., & Wu, T. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00898.x · Cited by 283
Optimizing Cancer Radiotherapy with 2-Deoxy-D-Glucose
Singh, D., Banerji, A. K., Dwarakanath, B. S. R., Tripathi, R. P., Gupta, J. P., Mathew, T. L., Ravindranath, T., & Jain, V. K. (2005) · Strahlentherapie und Onkologie · doi:10.1007/s00066-005-1320-z · Cited by 265
Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties
Gillard, M. R., Fuks, B., Leclercq, K., & Matagne, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.064 · Cited by 252
Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity
Kenda, B., Matagne, A., Talaga, P. E., Pasau, P., Differding, E., Lallemand, B., Frycia, A., Moureau, F., Klitgaard, H., Gillard, M. R., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030913e · Cited by 225
Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2008) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.09.005 · Cited by 225
Self-citation
Modulation of Hippocampal Excitability and Seizures by Galanin
Mazarati, A. M., Hohmann, J. G., Bacon, A., Liu, H., Sankar, R., Steiner, R. A., Wynick, D., & Wasterlain, C. G. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06276.2000 · Cited by 224
Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2A
Matagne, A., Margineanu, D., Kenda, B., Michel, P., & Klitgaard, H. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.198 · Cited by 223
Neurosteroid modulation of synaptic and extrasynaptic GABAA receptors
Herd, M. B., Belelli, D., & Lambert, J. J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.007 · Cited by 206
Galanin Modulation of Seizures and Seizure Modulation of Hippocampal Galanin in Animal Models of Status Epilepticus
Mazarati, A. M., Liu, H., Soomets, U., Sankar, R., Shin, D. H., Katsumori, H., Langel, Ü., & Wasterlain, C. G. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-23-10070.1998 · Cited by 180
Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam
Trenité, D. G. A. K.-N., Marescaux, C., Stodieck, S. R. G., Edelbroek, P. M., & Oosting, J. (1996) · Epilepsy Research · doi:10.1016/s0920-1211(96)00031-9 · Cited by 180
Guidelines for EEG in encephalopathy related to ESES/CSWS in children
Boer, M. S. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02211.x · Cited by 179
Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.09.001 · Cited by 179
Self-citation
Interleukin Converting Enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1β production
Ravizza, T., Noè, F. M., Zardoni, D., Vaghi, V., Sifringer, M., & Vezzani, A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.05.007 · Cited by 178
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P., & Perucca, E. (1999) · Epilepsy Research · doi:10.1016/s0920-1211(98)00108-9 · Cited by 178
Self-citation
A Pharmacology Primer: Theory, Applications, and Methods
Kenakin, T. (2006) · Cited by 173
SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy
Kaminski, R. M., Matagne, A., Leclercq, K., Gillard, M. R., Michel, P., Kenda, B., Talaga, P. E., & Klitgaard, H. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.11.021 · Cited by 168
Anticonvulsant and antiepileptic actions of 2‐deoxy‐D‐glucose in epilepsy models
Stafstrom, C. E., Ockuly, J. C., Murphree, L. J., Valley, M. T., Roopra, A., & Sutula, T. P. (2009) · Annals of Neurology · doi:10.1002/ana.21603 · Cited by 165
Galanin reduces release of endogeneous excitatory amino acids in the rat hippocampus
Zini, S., Roisin, M. P., Langel, Ü., Bartfai, T., & Ben-Ari, Y. (1993) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(93)90162-3 · Cited by 160
Adjunctive brivaracetam for refractory partial-onset seizures
French, J. A., Costantini, C., Brodsky, A. L., & von Rosenstiel, P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ec7f7f · Cited by 157
Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P., & Perucca, E. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(00)00171-6 · Cited by 152
Self-citation
The Second Galanin Receptor GalR2 Plays a Key Role in Neurite Outgrowth from Adult Sensory Neurons
Mahoney, S.-A., Hosking, R., Farrant, S., Holmes, F. E., Jacoby, A. S., Shine, J., Iismaa, T. P., Scott, M. K., Schmidt, R., & Wynick, D. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-02-00416.2003 · Cited by 149
Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself.
Reddy, D., & Rogawski, M. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39026-3 · Cited by 148
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males
Sargentini‐Maier, M. L., Rolan, P. E., Connell, J., Tytgat, D., Jacobs, T. G., Pigeolet, E., Riethuisen, J., & Stockis, A. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02829.x · Cited by 140
Benzodiazepines on trial: a research strategy for their rehabilitation
Costa, E., & Guidetti, A. (1996) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(96)10015-8 · Cited by 140
Valproic Acid: Second Generation
Bialer, M., & Yagen, B. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.007 · Cited by 139
Self-citation
Chemical properties of antiepileptic drugs (AEDs)
Bialer, M. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.006 · Cited by 139
Self-citation
Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial
Kerrigan, J., Shields, W. D., Nelson, T. Y., Bluestone, D. L., Dodson, W. E., Bourgeois, B. F. D., Pellock, J. M., Morton, L. D., & Monaghan, E. P. (2000) · Epilepsy Research · doi:10.1016/s0920-1211(00)00170-4 · Cited by 138
Chronic ingestion of 2-deoxy-d-glucose induces cardiac vacuolization and increases mortality in rats
Minor, R. K., Smith, D. L., Sossong, A. M., Kaushik, S., Poosala, S., Spangler, E. L., Roth, G. S., Lane, M. A., Allison, D. B., de Cabo, R., et al. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.11.025 · Cited by 133
Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man
Matagne, A., & Klitgaard, H. (1998) · Epilepsy Research · doi:10.1016/s0920-1211(98)00016-3 · Cited by 129
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men
Rolan, P. E., Sargentini‐Maier, M. L., Pigeolet, E., & Stockis, A. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03158.x · Cited by 123
Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure‐induced neurogenesis in the dentate gyrus
Mazarati, A. M., Lü, X., Kilk, K., Langel, Ü., Wasterlain, C. G., & Bartfai, T. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03449.x · Cited by 120
Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects
Sargentini‐Maier, M. L., Espié, P., Coquette, A., & Stockis, A. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017129 · Cited by 118
Fructose-1,6-Bisphosphate Has Anticonvulsant Activity in Models of Acute Seizures in Adult Rats
Lian, X., Khan, F. A., & Stringer, J. L. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3163-07.2007 · Cited by 115
Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage
Elliott‐Hunt, C. R., Pope, R. J. P., Vanderplank, P. A., & Wynick, D. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04239.x · Cited by 113
A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus
Ceolin, L., Bortolotto, Z. A., Bannister, N. J., Collingridge, G. L., Lodge, D., & Volianskis, A. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.02.035 · Cited by 108
Clinical Evaluation of Ganaxolone in Pediatric and Adolescent Patients with Refractory Epilepsy
Pieribone, V. A., Tsai, J., Soufflet, C., Rey, E., Shaw, K., Giller, E. L., & Dulac, O. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01182.x · Cited by 107
Tolerability and safety of perampanel: two randomized dose-escalation studies
Krauss, G. L., Bar, M., Biton, V., Klapper, J. A., Rektor, I., Vaičienė-Magistris, N., Squillacote, D., & Kumar, D. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2011.01588.x · Cited by 106
Assessment of Ganaxolone's Anticonvulsant Activity Using a Randomized, Double‐Blind, Presurgical Trial Design
Laxer, K. D., Blum, D. E., Abou‐Khalil, B. W., Morrell, M. J., Lee, D. A., Data, J. L., Monaghan, E. P., & the Ganaxolone Presurgical Study Group (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00324.x · Cited by 106
Regulation of Kindling Epileptogenesis by Hippocampal Galanin Type 1 and Type 2 Receptors: The Effects of Subtype-Selective Agonists and the Role of G-Protein-Mediated Signaling
Mazarati, A. M., Lundström, L., Sollenberg, U. E., Shin, D. H., Langel, Ü., & Sankar, R. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104703 · Cited by 102
Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model
Reddy, D. S., & Rogawski, M. A. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.01.009 · Cited by 100
Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice
Mazarati, A. M., Lü, X., Shinmei, S., Badie-Mahdavi, H., & Bartfai, T. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.06.052 · Cited by 99
Differential expression of connexins in trigeminal ganglion neurons and satellite glial cells in response to chronic or acute joint inflammation
Garrett, F. G., & Durham, P. L. (2008) · Neuron Glia Biology · doi:10.1017/s1740925x09990093 · Cited by 88
Seizures in dogs.
Podell, M. (1996) · PubMed · Cited by 85
Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats
Mazarati, A. M., Halászi, E., & Telegdy, G. (1992) · Brain Research · doi:10.1016/0006-8993(92)91179-i · Cited by 84
The galanin peptide family in inflammation
Lang, R., & Kofler, B. (2010) · Neuropeptides · doi:10.1016/j.npep.2010.10.005 · Cited by 78
A Pharmacology Primer
(2006) · Elsevier eBooks · doi:10.1016/b978-0-12-370599-0.x5000-x · Cited by 76
Seizures in Dogs
Podell, M. (1996) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/s0195-5616(96)50105-1 · Cited by 76
Tonabersat Inhibits Trigeminal Ganglion Neuronal‐Satellite Glial Cell Signaling
Damodaram, S., Thalakoti, S., Freeman, S. E., Garrett, F. G., & Durham, P. L. (2008) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2008.01262.x · Cited by 70
Brivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture
Zona, C., Pieri, M., Carunchio, I., Curcio, L., Klitgaard, H., & Margineanu, D. G. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.09.024 · Cited by 70
A new derivative of valproic acid amide possesses a broad‐spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage
White, H. S., Alex, A. B., Pollock, A., Hen, N., Shekh‐Ahmad, T., Wilcox, K. S., McDonough, J. H., Stables, J. P., Kaufmann, D., Yagen, B., et al. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03338.x · Cited by 67
Self-citation
Anticonvulsant and proconvulsant actions of 2‐deoxy‐ d ‐glucose
Ga̧sior, M., Yankura, J., Hartman, A. L., French, A., & Rogawski, M. A. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02593.x · Cited by 63
Design, Synthesis, and Characterization of High-Affinity, Systemically-Active Galanin Analogues with Potent Anticonvulsant Activities
Bulaj, G. W., Green, B. R., Lee, H.-K., Robertson, C. R., White, K. L., Zhang, L., Sochanska, M., Flynn, S. P., Scholl, E. A., Pruess, T. H., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801088x · Cited by 62
Self-citation
Brivaracetam Disposition in Renal Impairment
Sargentini‐Maier, M. L., Sokalski, A., Boulanger, P., Jacobs, T. G., & Stockis, A. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011431457 · Cited by 61
Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors
Mazarati, A. M., & Lü, X. (2005) · Neuropeptides · doi:10.1016/j.npep.2004.12.003 · Cited by 60
Anticonvulsant Efficacy of the Low‐affinity Partial Benzodiazepine Receptor Agonist ELB 138 in a Dog Seizure Model and in Epileptic Dogs with Spontaneously Recurrent Seizures
Löscher, W., Potschka, H., Rieck, S., Tipold, A., & Rundfeldt, C. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.21204.x · Cited by 57
Contemporary Neurology Series
Swanson, P. D. (1970) · Neurology · doi:10.1212/wnl.20.1.102 · Cited by 54
Evaluation of epileptic dogs as an animal model of human epilepsy.
Löscher, W., Schwartz-Porsche, D., Frey, H. ‐., & Schmidt, D. (1985) · PubMed · Cited by 53
Developing Novel Antiepileptic Drugs: Characterization of NAX 5055, a Systemically-Active Galanin Analog, in Epilepsy Models
White, H. S., Scholl, E. A., Klein, B. D., Flynn, S. P., Pruess, T. H., Green, B. R., Zhang, L., & Bulaj, G. W. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.01.001 · Cited by 52
Self-citation
Pharmacokinetics of anti‐epileptic drugs in the dog: a review
Frey, H. ‐., & Löscher, W. (1985) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.1985.tb00951.x · Cited by 52
Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double‐blind, controlled, add‐on clinical trial
Bersudsky, Y., Applebaum, J., Gaiduk, Y., Sharony, L., Mishory, A., Podberezsky, A., Agam, G., & Belmaker, R. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00828.x · Cited by 47
Pharmacokinetics, anticonvulsant efficacy and adverse effects of the beta-carboline abecarnil, a novel ligand for benzodiazepine receptors, after acute and chronic administration in dogs.
Löscher, W., Hönack, D., Scherkl, R., Hashem, A., & Frey, H. ‐. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22926-3 · Cited by 43
Synthesis and Evaluation of Antiallodynic and Anticonvulsant Activity of Novel Amide and Urea Derivatives of Valproic Acid Analogues
Kaufmann, D., Bialer, M., Shimshoni, J. A., Devor, M. G., & Yagen, B. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901229s · Cited by 41
Self-citation
Behavioral, cognitive, and safety profile of 2-deoxy-2-glucose (2DG) in adult rats.
Ockuly, J., Gielissen, J. M., Levenick, C. V., Zeal, C., Groble, K., Munsey, K., Sutula, T., & Stafstrom, C. (2012) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.04.012 · Cited by 37
Engineering Galanin Analogues That Discriminate between GalR1 and GalR2 Receptor Subtypes and Exhibit Anticonvulsant Activity following Systemic Delivery
Robertson, C. R., Scholl, E. A., Pruess, T. H., Green, B. R., White, H. S., & Bulaj, G. W. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9018349 · Cited by 36
Self-citation
Structural Requirements for a Lipoamino Acid in Modulating the Anticonvulsant Activities of Systemically Active Galanin Analogues
Zhang, L., Robertson, C. R., Green, B. R., Pruess, T. H., White, H. S., & Bulaj, G. W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801397w · Cited by 36
Self-citation
GABAergic transmission in temporal lobe epilepsy: The role of neurosteroids
Joshi, S., Rajasekaran, K., & Kapur, J. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.10.028 · Cited by 35
Effect of brivaracetam on cardiac repolarisation – a thorough QT study
Rosillon, D., Astruc, B., Hulhoven, R., Meeus, M.-A., Troenaru, M., Watanabe, S., & Stockis, A. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802278453 · Cited by 35
The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers
Elman, I., Sokoloff, L., Adler, C. M., Weisenfeld, N., & Breier, A. F. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01137-8 · Cited by 30
Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid
Kaufmann, D., Yagen, B., Minert, A., Wlodarczyk, B. J., Finnell, R. H., Schurig, V., Devor, M. G., & Bialer, M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.03.004 · Cited by 27
Self-citation
Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats
Detrait, E., Leclercq, K., Löscher, W., Potschka, H., Niespodziany, I., Hanon, É., Kaminski, R. M., Matagne, A., & Lamberty, Y. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.06.014 · Cited by 23
Comparative studies of the influence of various K+ concentrations on the action of K-strophanthidin, digitoxin and strophanthidin-3-bromoacetate on papillary muscle and on membrane-atpase of guinea pig hearts
Fricke, U., & Klaus, W. (1971) · European Journal of Pharmacology · doi:10.1016/0014-2999(71)90070-7 · Cited by 22
The antiepileptic drug AWD 131–138 stimulates different recombinant isoforms of the GABAA receptor through the benzodiazepine binding site
Sigel, E., Baur, R., Netzer, R., & Rundfeldt, C. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00186-4 · Cited by 22
AWD-131-138
Rostock, A., Tober, C., Dost, R., Rundfeldt, C., Bartsch, R., Egerland, U., Stark, B., Schupke, H., Kronbach, T., Lankau, H., et al. (1998) · Drugs of the Future · doi:10.1358/dof.1998.023.03.450427 · Cited by 20
Physiologically Based Pharmacokinetic/Pharmacodynamic Animal‐to‐Man Prediction of Therapeutic Dose in a Model of Epilepsy
Brochot, A., Zamacona, M. K., & Stockis, A. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00536.x · Cited by 19
Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas
Raez, L. E., Langmuir, V. K., Tolba, K., Rocha‐Lima, C., Papadopoulos, K., Kroll, S., Brawer, M. K., Rosenblatt, J. D., Ricart, A. D., & Lampidis, T. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14025 · Cited by 16
Evaluation of the novel antiepileptic drug, AWD 131-138, for benzodiazepine-like discriminative stimulus and reinforcing effects in squirrel monkeys
Yaşar, S. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01533-4 · Cited by 9
Pharmacokinetics of Brivaracetam in Subjects With Hepatic Impairment and in Matched Healthy Controls
Horsmans, Y., Sargentini‐Maier, M. L., & Stockis, A. (2009) · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · Cited by 8
LOCAL DELIVERY OF ADENOSINE HAS AN ANTIEPILEPTIC EFFECT IN RATS WITH SPONTANEOUS SEIZURES
Dycke, A. V., Raedt, R., Dauwe, I., Wyckhuys, T., Herdt, V. D., Tahry, R. E., Meurs, A., Vonck, K. E. J., Wadman, W. J., & Boon, P. (2008) · Ghent University Academic Bibliography (Ghent University) · Cited by 8
Pharmacokinetics of Brivaracetam in Subjects With Hepatic Impairment and in Matched Healthy Controls
Stockis, A., Horsmans, Y., Sargentini-Maier, M. L., Boulton, M., & 62nd Annual Meeting of the American-Epilepsy-Society (2008) · Digital Access to Libraries · Cited by 2

Research works printed but not linked: 13

Biton, 2009, Brivaracetam as adjunctive treatment of refractory partial-onset seizures in adults: results from two randomized, double-blind, placebo-controlled trials, Epilepsia, 50, 106
Brodsky, 2007, Safety and tolerability of brivaracetam (ucb 34714) as adjunctive treatment in adults with refractory partial-onset seizures, Epilepsia, 48, 342
Kwan, 2009, Safety and tolerability of brivaracetam as adjunctive treatment in adults with refractory epilepsy: randomized, double-blind, placebo-controlled trial, Epilepsia, 50, 107
Niespodziany, 2009, Brivaracetam modulates Na+ currents expressed in a neuroblastoma cell line compared with carbamazepine, Epilepsia, 50, 107
Rostock, 1998, AWD 131-138 is a potential novel anxiolytic without sedation and amnesia: a comparison with diazepam and buspirone, Naunyn-Schmied. Arch. Pharmacol., 358, R68
Sargentini-Maier, 2008, Pharmacokinetics, safety and tolerability of brivaracetam in healthy elderly subjects, Epilepsia, 49, 452
Stafstrom, 2007, 2-Deoxyglucose effects on spatial learning and exploratory behavior in rodents, Epilepsia, 48, 299
Stockis, 2009, Interaction study between brivaracetam and a combination oral contraceptive, Epilepsia, 50, 96
Sutula, 2008, Dose-response and time course of action of disease-modifying effects of 2DG on kindling progression: effectiveness of administration after seizures, Epilepsia, 49, 382
Tober, 1998, AWD 131-138: a derivative of a series of imidazolinones with anticonvulsant activity, Naunyn-Schmied. Arch. Pharmacol., 358, R68
Tober, 1999, Anticonvulsant activity of AWD 131-138 in genetic animal models of epilepsy, Naunyn-Schmied. Arch. Pharmacol., 359, R97
Van Paesschen, 2007, Efficacy and tolerability of 50 and 150mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial onset epilepsy, Epilepsia, 48, 329
Wasterlain, 2009, Short-term and long-term effects of brivaracetam in an animal model of status epilepticus, Epilepsia, 50, 13

Sorted by citations

Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
Löscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019539 · Cited by 967
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0217-x · Cited by 928
New avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 696
Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial
Krauss, G. L., Klein, P., Brandt, C., Lee, S. K., Milanov, I. G., Milovanović, M., Steinhoff, B. J., & Kamin, M. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30399-0 · Cited by 347
Pathogenesis of acute stroke and the role of inflammasomes
Fann, D. Y., Lee, S.-Y., Manzanero, S., Chunduri, P., Sobey, C. G., & Arumugam, T. V. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.09.004 · Cited by 334

See all 244

Authors: Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S.
Affiliations: Hebrew University of Jerusalem (IL)
Oslo University Hospital (NO)
University of Washington (US)
University of Pavia (IT)
Karolinska Institutet (SE)
University of Utah (US)
Corresponding author: Bialer, Meir
ORCID: Bialer, Meir
Johannessen, Svein I.
Levy, René H.
Perucca, Emilio
Tomson, Torbjörn
White, H. Steve
Venue: Epilepsy Research
Publisher: Elsevier BV
Published: 2013-01
Volume: 103
Issue: 1
Pages: 2-30
ISSN: 0920-1211 (ISSN-L)
DOI: 10.1016/j.eplepsyres.2012.10.001
OpenAlex: W2203865877
Cited by: 243
References: 98
Citations by year: 2026: 10 · 2025: 12 · 2024: 14 · 2023: 13 · 2022: 20 · 2021: 17 · 2020: 32 · 2019: 12 · 2018: 10 · 2017: 19 · 2016: 17 · 2015: 23 · 2014: 24 · 2013: 20
FWCI: 2.88
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/3.0/ (vor, 196 d)
Locations: Epilepsy Research (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
Funders: National Institutes of Health
UCB Pharma
Topics: Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: antiepileptic drugs, drug development, preclinical pharmacology, clinical pharmacology, brivaracetam, 2-deoxyglucose, ganaxolone, perampanel, AMPA receptor antagonists, tonabersat, retigabine, ezogabine, VX-765, epilepsy
MeSH terms: Animals, Anticonvulsants, Clinical Trials as Topic, Congresses as Topic, Epilepsy, Humans, Israel, Drugs, Investigational, Research Report

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks